217 F. Supp. 3d 756
D. Del.2016Background
- Orexo sued Actavis after Actavis filed an ANDA to market a generic sublingual buprenorphine/naloxone tablet; dispute concerned asserted claims of U.S. Pat. Nos. 8,454,996 (the ’996 patent) and 8,940,330 (the ’330 patent).
- The ’996 claims a sublingual tablet with water-soluble carrier particles bearing microparticles of buprenorphine as an interactive mixture plus a bio/mucoadhesive; claim 2 adds an “essentially water free” limitation.
- The ’330 claims a sublingual tablet with buprenorphine microparticles on carrier particles (in contact with citric acid particles), naloxone, and a listed disintegrant; Orexo’s commercial product Zubsolv practices the asserted claims.
- Prior art included: interactive-mixture teachings (EP ’725 and related literature), sublingual buprenorphine products (e.g., Suboxone, Temgesic), bioadhesive references (’686, ’386 patents), and later references addressing interactive mixtures with naloxone and pH/buffer effects (e.g., ’443 application, ’832 patent).
- Bench trial findings: court held asserted claims of the ’996 patent not obvious and infringed by Actavis; held asserted claims of the ’330 patent invalid as obvious.
Issues
| Issue | Orexo's Argument | Actavis' Argument | Held |
|---|---|---|---|
| Obviousness of asserted claims of the ’996 patent | The combination of interactive mixtures plus mucoadhesive for sublingual use produced unexpected results; prior art taught away and did not disclose sublingual use of ordered mixtures | Prior art disclosed interactive mixtures, sublingual buprenorphine tablets, and bioadhesives; a person of ordinary skill would be motivated to combine them | Court: Actavis failed to prove by clear and convincing evidence that a person of ordinary skill would be motivated to combine the competing prior-art teachings to reach the ’996 claims — claims are valid (not obvious) |
| Obviousness of asserted claims of the ’330 patent | The claimed pH-timing effect and separation of citric acid particles from buprenorphine produced unexpected bioavailability; prior art taught away | Prior art (Suboxone, EP/’443 interactive-mixture teachings, ’832 pH/buffer teachings) provided motivation and reasonable expectation of success to reformulate as an interactive mixture with citric acid carriers | Court: Actavis proved by clear and convincing evidence motive and expectation of success; secondary factors (some increased bioavailability) did not overcome obviousness — claims 1, 3–6, 8–10 invalid as obvious |
| Infringement of asserted claims of the ’996 patent by Actavis’ ANDA products | Orexo: testing of lab-made precompression blends, Raman/SEM imaging of Actavis tablets, blend-uniformity data, and expert opinion show interactive mixtures meeting "presented/Adhered/presented upon" limitations | Actavis: criticized Orexo’s lab-scale blends, documentary errors, lack of intermediate production, and argued tablet-level analysis cannot prove interactive mixtures | Court: On preponderance of evidence, Orexo proved Actavis’ tablets infringe the asserted ’996 claims (interactive mixture present); documentation flaws did not defeat infringement finding |
| Remedy / Judgment | Orexo sought relief for infringement of the valid ’996 claims; Actavis sought judgment of invalidity for ’330 claims | Actavis sought declaratory judgment of noninfringement/invalidation where appropriate | Court: Entered judgment finding asserted ’996 claims valid and infringed; asserted ’330 claims invalid; appropriate judgment ordered |
Key Cases Cited
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (framework for obviousness, including motivation to combine and "obvious to try" analysis)
- Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966) (Graham factors govern obviousness inquiry)
- PharmaStem Therapeutics, Inc. v. ViaCell, Inc., 491 F.3d 1342 (Fed. Cir. 2007) (reasonable expectation of success requirement)
- PowerOasis, Inc. v. T-Mobile USA, Inc., 522 F.3d 1299 (Fed. Cir. 2008) (deference owed to PTO when only PTO-considered prior art is relied upon)
- Microsoft Corp. v. i4i Ltd. P’ship., 564 U.S. 91 (2011) (invalidity defenses require clear and convincing evidence)
- Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd., 821 F.3d 1359 (Fed. Cir. 2016) (motivation-to-combine and reasonable-expectation-of-success standard for obviousness of combinations)
- Exergen Corp. v. Wal-Mart Stores, Inc., 575 F.3d 1312 (Fed. Cir. 2009) (direct infringement requires each claim limitation be performed)
- Spectrum Pharm., Inc. v. Sandoz Inc., 802 F.3d 1326 (Fed. Cir. 2015) (claim construction and infringement interplay; burden of proof for infringement)